Today on The Alden Report, I welcome Doug Drysdale who is attempting to revolutionize the treatment of mental health disorders and addictions by developing novel therapies using psychedelics. An experienced Corporate Director and CEO, Doug has chaired the board of directors of a NASDAQ-listed company and has built and turned-around three pharmaceutical companies as CEO over the last 12 years. During Doug’s 30 plus years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital. He was also recognized as Entrepreneur of the Year by Ernst and Young in 2012.
Currently, Doug is the CEO of Cybin which is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
This is a fascinating discussion that you’re not going to want to miss. We even discuss Cybin’s popularity with individuals such as Tony Robbins and Deepak Chopra.
Thank you very much to Doug Drysdale for joining us this week on The Alden Report.
For more information on Doug and his company, you can visit: https://cybin.com/